The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an…
Novartis AG today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. “Avidity’s breakthrough science combined with Novartis capabilities will…
GSK announced the completion of its previously announced acquisition of RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal…
To turn ambition into action, Servier launched a global partnership with Women in Tech, which aims to reach 5 million women and girls in Science, Technology, Engineering and Mathematics (STEM) by 2030. It’s a new initiative for long-term impact, employee…
Pfizer today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off…
This year again, Servier is honored with the Gallup Exceptional Workplace Award. This distinction highlights organizations that integrate employee engagement at the heart of their strategy and corporate culture. While receiving this award last year was a major recognition, obtaining…
Merck, known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site. This expansion of our Durham plant is a…
Roche announced today that the World Health Organization (WHO) has awarded the cobas® HPV test prequalification designations for use on the cobas® 5800 system and for self-collected samples on the cobas® 5800, 6800 and 8800 systems. These new prequalification designations come…
AbbVie announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius’ lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1…
AbbVie announced that the independent directors of the board have selected Roxanne Austin as lead independent director, effective July 1, 2024. Ms. Austin succeeds Glenn F. Tilton, who has served as lead independent director since 2013. Mr. Tilton will continue to serve…